Literature DB >> 33580074

Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

David A Montero1,2, Felipe Del Canto1, Juan C Salazar1, Sandra Céspedes1, Leandro Cádiz1, Mauricio Arenas-Salinas3, José Reyes4, Ángel Oñate4, Roberto M Vidal5,6.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) cause diarrhea and dysentery, which may progress to hemolytic uremic syndrome (HUS). Vaccination has been proposed as a preventive approach against STEC infection; however, there is no vaccine for humans and those used in animals reduce but do not eliminate the intestinal colonization of STEC. The OmpT, Cah and Hes proteins are widely distributed among clinical STEC strains and are recognized by serum IgG and IgA in patients with HUS. Here, we develop a vaccine formulation based on two chimeric antigens containing epitopes of OmpT, Cah and Hes proteins against STEC strains. Intramuscular and intranasal immunization of mice with these chimeric antigens elicited systemic and local long-lasting humoral responses. However, the class of antibodies generated was dependent on the adjuvant and the route of administration. Moreover, while intramuscular immunization with the combination of the chimeric antigens conferred protection against colonization by STEC O157:H7, the intranasal conferred protection against renal damage caused by STEC O91:H21. This preclinical study supports the potential use of this formulation based on recombinant chimeric proteins as a preventive strategy against STEC infections.

Year:  2020        PMID: 33580074     DOI: 10.1038/s41541-020-0168-7

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  65 in total

Review 1.  Molecular mechanisms that mediate colonization of Shiga toxin-producing Escherichia coli strains.

Authors:  Mauricio J Farfan; Alfredo G Torres
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection.

Authors:  David Montero; Paz Orellana; Daniela Gutiérrez; Daniela Araya; Juan Carlos Salazar; Valeria Prado; Angel Oñate; Felipe Del Canto; Roberto Vidal
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

Review 4.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis.

Authors:  Shannon E Majowicz; Elaine Scallan; Andria Jones-Bitton; Jan M Sargeant; Jackie Stapleton; Frederick J Angulo; Derrick H Yeung; Martyn D Kirk
Journal:  Foodborne Pathog Dis       Date:  2014-04-21       Impact factor: 3.171

Review 6.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 7.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

8.  Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains.

Authors:  Brian K Coombes; Mark E Wickham; Mariola Mascarenhas; Samantha Gruenheid; B Brett Finlay; Mohamed A Karmali
Journal:  Appl Environ Microbiol       Date:  2008-02-01       Impact factor: 4.792

9.  Cumulative acquisition of pathogenicity islands has shaped virulence potential and contributed to the emergence of LEE-negative Shiga toxin-producing Escherichia coli strains.

Authors:  David Arturo Montero; Felipe Del Canto; Juliana Velasco; Rocío Colello; Nora Lia Padola; Juan Carlos Salazar; Carla San Martin; Angel Oñate; Jorge Blanco; David A Rasko; Carmen Contreras; Jose Luis Puente; Flemming Scheutz; Eelco Franz; Roberto M Vidal
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

10.  Locus of Adhesion and Autoaggregation (LAA), a pathogenicity island present in emerging Shiga Toxin-producing Escherichia coli strains.

Authors:  David A Montero; Juliana Velasco; Felipe Del Canto; Jose L Puente; Nora L Padola; David A Rasko; Mauricio Farfán; Juan C Salazar; Roberto Vidal
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.